Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Issue 7 (4th May 2018)

• Record Type: Journal Article
• Authors: Mayo, Rebeca; Crespo, Javier; Martínez‐Arranz, Ibon; Banales, Jesus M; Arias, Mayte; Mincholé, Itziar; Aller de la Fuente, Rocío; Jimenez‐Agüero, Raúl; Alonso, Cristina; de Luis, Daniel A.; Vitek, Libor; Stritesky, Jan; Caballería, Joan; Romero‐Gómez, Manuel; Martín‐Duce, Antonio; Mugüerza Huguet, Jose Maria; Busteros‐Moraza, José Ignacio; Idowu, Michael O.; Castro, Azucena; Martínez‐Chantar, M. Luz; Ortiz, Pablo; Bruha, Radan; Lu, Shelly C.; Bedossa, Pierre; Noureddin, Mazen; Sanyal, Arun J.; Mato, José M.
• Is Part Of: Hepatology communications. Volume 2:Issue 7(2018)
• Page Start: 807
• Page End: 820
• Publication Date: 2018-05-04
• Subjects: Hepatology -- Periodicals; Liver -- Diseases -- Periodicals; Liver Diseases; Gastroenterology; Periodicals; Fulltext; Internet Resources; Periodicals; 616.36
• DOI: 10.1002/hep4.1188
• Languages: English
• ISSNs: 2471-254X

Abstract

Abstract : Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease worldwide and includes a broad spectrum of histologic phenotypes, ranging from simple hepatic steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). While liver biopsy is the reference gold standard for NAFLD diagnosis and staging, it has limitations due to its sampling variability, invasive nature, and high cost. Thus, there is a need for noninvasive biomarkers that are robust, reliable, and cost effective. In this study, we measured 540 lipids and amino acids in serum samples from biopsy‐proven subjects with normal liver (NL), NAFL, and NASH. Using logistic regression analysis, we identified two panels of triglycerides that could first discriminate between NAFLD and NL and second between NASH and NAFL. These noninvasive tests were compared to blinded histology as a reference standard. We performed these tests in an original cohort of 467 patients with NAFLD (90 NL, 246 NAFL, and 131 NASH) that was subsequently validated in a separate cohort of 192 patients (7 NL, 109 NAFL, 76 NASH). The diagnostic performances of the validated tests showed an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.88 ± 0.05, 0.94, and 0.57, respectively, for the discrimination between NAFLD and NL and 0.79 ± 0.04, 0.70, and 0.81, respectively, for the discrimination between NASH and NAFL. When the analysis was performed excluding patients with glucose levels >136 mg/dL, the area under the receiver operating characteristic curve for the discrimination between NASH and NAFL increased to 0.81 ± 0.04 with sensitivity and specificity of 0.73 and 0.80, respectively. Conclusion: The assessed noninvasive lipidomic serum tests distinguish between NAFLD and NL and between NASH and NAFL with high accuracy. ( Hepatology Communications 2018;2:807‐820)